• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by NKGen Biotech Inc.

    2/28/25 5:46:18 PM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NKGN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    NKGen Biotech, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    65488A101

    (CUSIP Number)


    10/17/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    65488A101


    1Names of Reporting Persons

    PATHSTONE FAMILY OFFICE, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,797,661.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,797,661.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.91 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  Concentrated stock position owned by a client in a managed account.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    NKGen Biotech, Inc.
    (b)Address of issuer's principal executive offices:

    3001 DAIMLER ST, SANTA ANA, CALIFORNIA 92705
    Item 2. 
    (a)Name of person filing:

    PATHSTONE FAMILY OFFICE, LLC
    (b)Address or principal business office or, if none, residence:

    10 Sterling Blvd Suite 402 ENGLEWOOD, New Jersey 07631
    (c)Citizenship:

    PATHSTONE FAMILY OFFICE, LLC - DELAWARE
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    65488A101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,797,661
    (b)Percent of class:

    7.91  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    PATHSTONE FAMILY OFFICE, LLC - 0

     (ii) Shared power to vote or to direct the vote:

    PATHSTONE FAMILY OFFICE, LLC - 0

     (iii) Sole power to dispose or to direct the disposition of:

    PATHSTONE FAMILY OFFICE, LLC - 0

     (iv) Shared power to dispose or to direct the disposition of:

    PATHSTONE FAMILY OFFICE, LLC - 2,797,661

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    This is a concentrated position in a single client account we manage.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PATHSTONE FAMILY OFFICE, LLC
     
    Signature:Rebecca A Judd
    Name/Title:Director
    Date:02/27/2025
    Get the next $NKGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NKGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NKGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

      4 - NKGen Biotech, Inc. (0001845459) (Issuer)

      5/7/25 4:05:15 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Graf Acquisition Partners Iv Llc disposed of 63,634 shares (SEC Form 4)

      4 - NKGen Biotech, Inc. (0001845459) (Issuer)

      12/26/24 7:20:39 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Graf Acquisition Partners Iv Llc disposed of 290,603 shares (SEC Form 4)

      4 - NKGen Biotech, Inc. (0001845459) (Issuer)

      12/23/24 4:01:35 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

      4 - NKGen Biotech, Inc. (0001845459) (Issuer)

      5/7/25 4:05:15 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations

      New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disclosed AlpineBrook convertible notes. SANTA ANA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that its Chairman & Chief Executive Officer, Paul Y. Song, M.D., has invested $2.65 million cash, derived from the recent successful sale of another biotech busin

      5/8/25 8:05:00 AM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

      SANTA ANA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced an upcoming presentation on Phase 1 clinical data from the Company's Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer's disease (AD), at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which will take place in New Orleans, Louisiana from May 13–17, 2025. Presentation Details Title: Us

      5/7/25 8:00:00 AM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition

      SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will be speaking at the 7th China International Biotechnology Conference & Exhibition (BIOTEC-CHINA 2025), to be held in Beijing, China, April 16-18, 2025. BIOTEC-CHINA 2025 is a premier gathering of biotechnology and pharmaceutical professionals from across the globe. With close to 1,500 attendees, the event offers a unique op

      4/14/25 8:00:00 AM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKGN
    SEC Filings

    See more
    • NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NKGen Biotech, Inc. (0001845459) (Filer)

      5/8/25 8:06:18 AM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - NKGen Biotech, Inc. (0001845459) (Filer)

      5/1/25 4:05:08 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - NKGen Biotech, Inc. (0001845459) (Filer)

      4/22/25 4:05:14 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKGN
    Leadership Updates

    Live Leadership Updates

    See more
    • NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site

      SANTA ANA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator ("PI") for its Phase 2a clinical trial of troculeucel, expanded enhanced autologous NK cell therapy, for the treatment of moderate Alzheimer's disease (NCT06189963). In addition to Dr. Fletcher's appointment as National PI, NKGen is pleased to announce AdventHealth Research Institute, Neuroscience Research in Orl

      2/19/25 8:00:00 AM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors

      SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Gottardis is the owner of, and has served as a consultant at, Gottardis Biotech LLC, a biopharmaceuticals and research and development consultancy firm, since February 2023. Dr. Gottardi

      7/15/24 8:05:00 AM ET
      $JNJ
      $NKGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $NKGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by NKGen Biotech Inc.

      SC 13G - NKGen Biotech, Inc. (0001845459) (Subject)

      8/22/24 5:22:55 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by NKGen Biotech Inc. (Amendment)

      SC 13G/A - NKGen Biotech, Inc. (0001845459) (Subject)

      5/10/24 2:42:14 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKGN
    Financials

    Live finance-specific insights

    See more
    • NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

      – SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer's Disease, expect to initiate Phase I/IIa by year end – SNK02 Phase I allogeneic clinical program continues to progress; anticipated preliminary solid tumor data readout and IND filing for Parkinson's Disease in 1Q24 SANTA ANA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (NASDAQ:NKGN) (NKGen or the Company), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (NK) cell therapeutics, today announced its financial results for the

      11/14/23 4:48:03 PM ET
      $NKGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care